Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer
1998

Cisplatin-Induced Hearing Loss in Testicular Cancer Patients

Sample size: 86 publication Evidence: high

Author Information

Author(s): C Bokemeyer, CC Berger, JT Hartmann, C Kollmannsberger, H-J Schmoll, MA Kuczyk, L Kanz

Primary Institution: Eberhard-Karls-University Medical Center II, Tubingen

Hypothesis

What are the risk factors for cisplatin-induced ototoxicity in patients with testicular cancer?

Conclusion

Cisplatin-related ototoxicity affects about 20% of testicular cancer patients, with higher risks associated with cumulative doses over 600 mg/m².

Supporting Evidence

  • 20% of patients experienced persistent ototoxic symptoms.
  • 42% of audiograms showed hearing loss compatible with cisplatin-induced damage.
  • High cumulative doses of cisplatin significantly increased the risk of ototoxicity.
  • Previous noise exposure increased the risk of ototoxicity by threefold.
  • Vincristine doses were associated with reversible ototoxic symptoms.

Takeaway

Some people who get treated for testicular cancer with a medicine called cisplatin might have trouble hearing afterward, especially if they got a lot of it.

Methodology

Patients' hearing was tested using pure-tone audiometry, and their medical histories were reviewed for risk factors.

Potential Biases

Recall bias may affect the accuracy of reported hearing issues.

Limitations

The study only included patients who had been in complete remission for at least 12 months.

Participant Demographics

Median age of participants was 31 years, with a range from 21 to 53 years.

Statistical Information

P-Value

P < 0.0001 for cumulative dose of cisplatin; P = 0.006 for history of noise exposure; P = 0.001 for vincristine dose.

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication